

March 4, 2019

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) today announced that the following organizational realignment and changes in Executive Officers and other key positions, effective April 1, 2019:

I. Organizational Realignment (effective April 1, 2019)

Corporate Departments

1. Corporate Communications is created.

In order to strengthen communications to stakeholders through integrated CSR activities and public relations (PR) / investor relations (IR) activities, Corporate Communications will be created and the functions of CSR and PR/IR of Corporate Governance will be transferred to Corporate Communications.

2. Frontier Business Office is created.

To meet the future medical needs of society, where people will seek a diverse range of well-being, Sumitomo Dainippon Pharma is striving to establish a new medical care by pioneering frontier area in the healthcare sector. Our goal is to offer new value via contribution to the well-being of people in an area other than treatment of disease by pharmaceutical products through application of the latest digital technology based on the wealth of knowledge that we have built up over many years in the pharmaceutical business. As such, a Frontier Business Office will be created for commercialization of business in the frontier area by facilitating planning and promotion of in-house projects, alliances with outside institutions, and establishment of a global framework.

Drug Research (Division)

External Innovation Development Office is renamed to External Innovation.

Technology Research & Development (Division)

Process Chemistry Research & Development Laboratories is renamed to Process Research & Development Laboratories.

Manufacturing (Division)

1. The Ibaraki Plant and Ehime Plant will be closed.

With a view toward establishing a robust business operating structure to respond flexibly to changes in the business environment, Sumitomo Dainippon Pharma will close its Ibaraki Plant and Ehime Plant by the end of fiscal 2018, thus consolidating production into the Suzuka Plant and Oita Plant.

(Please see the press release dated December 26, 2014 for the reorganization of production sites.)

2. Engineering is dissolved and its functions are transferred to Suzuka Plant.

II. Changes in Executive Officers

(1) Promotions (effective April 1, 2019)

Member, Board of Directors, Executive Vice President
Hitoshi Odagiri (currently Member, Board of Directors, Senior Executive Officer)

Member, Board of Directors, Senior Executive Officer
Toru Kimura (currently Member, Board of Directors, Executive Officer)

Senior Executive Officer
Hiroyuki Baba (currently Executive Officer)

(2) New Executive Officers (effective April 1, 2019)

Takuya Taguchi (currently Deputy Executive Director, Sales & Marketing Division Senior Director, Sales & Marketing Management)

Shinichiro Katayanagi (currently Executive Vice President, Sunovion Pharmaceuticals Inc. Senior Strategic Officer — North America non-oncology business)

(3) Retiring Executive Officers (effective March 31, 2019)

Nobuyuki Hara (currently Member, Board of Directors, Executive Officer Executive Director, Corporate Regulatory Compliance & Quality Assurance Division; Regulatory Affairs; Medical Information; Medical Affairs; Drug Development Division Deputy Head of Japan Business Unit)

Mitsuyuki Taniguchi (currently Executive Officer Deputy Executive Director, Sales & Marketing Division)

(4) Changes in the positions assumed by Executive Officers (effective April 1, 2019)

Position as of April 1, 2019	Current position	Name
Member, Board of Directors, Senior Executive Officer Senior Executive Research Director, Drug Research Division; Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Regenerative & Cellular Medicine Manufacturing Plant Chief Research Officer	Member, Board of Directors, Executive Officer Senior Executive Research Director, Drug Research Division; Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Regenerative & Cellular Medicine Manufacturing Plant	Toru Kimura
Senior Executive Officer Executive Director, Corporate Regulatory Compliance & Quality Assurance Division; Regulatory Affairs; Medical Information; Medical Affairs; Drug Development Division Deputy Head of Japan Business Unit	Senior Executive Officer Chairman and CEO, Sunovion Pharmaceuticals Inc.	Nobuhiko Tamura
Senior Executive Officer Global Corporate Strategy; IT Management & Digital Transformation; Frontier Business Office	Executive Officer Global Corporate Strategy; Legal Affairs; Intellectual Property; IT Management & Digital Transformation	Hiroyuki Baba
Executive Officer Corporate Communications; Human Resources	Executive Officer Corporate Governance (External Communications); Human Resources	Atsuko Higuchi
Executive Officer Corporate Governance; Legal Affairs; Intellectual Property	Executive Officer Senior Director, Corporate Governance	Kazuhiro Takada
Executive Officer Executive Vice President and Chief Corporate Strategy Officer, Sunovion Pharmaceuticals Inc.	Executive Vice President, Sunovion Pharmaceuticals Inc. Senior Strategic Officer — North America non-oncology business	Shinichiro Katayanagi
Executive Officer President and CEO, Sunovion Pharmaceuticals Inc.	Executive Officer Executive Vice President and CMO, Sunovion Pharmaceuticals Inc. Head of Global Clinical Development for Sumitomo Dainippon Pharma Group	Antony Loebel

III. Changes in Personnel (effective April 1, 2019)

Corporate Departments

Position as of April 1, 2019	Current position	Name
Senior Director, Corporate Secretariat; External Affairs	Senior Director, External Affairs Senior Director, Corporate Secretariat	Tomokazu Nagano
Senior Director, External Affairs	Director, External Affairs & Pricing Group, External Affairs	Atsuji Hirota
Senior Director, Corporate Governance	Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.	Masaki Yamamoto
Senior Director, Corporate Communications	Senior Director, Medical Information	Miwako Harada
Senior Director, Medical Information	Director, Information Management Group, Medical Information	Keiko Hirano
Senior Director, Global Oncology Office	Boston Biomedical, Inc. Senior Oncology Business Officer	Tsutomu Nakagawa
Senior Director, DSP Cancer Institute	Senior Director, Global Oncology Office Senior Director, DSP Cancer Institute	Yasushi Matsuki
Senior Director, Frontier Business Office	Director, R&D Strategy Group, Global Corporate Strategy	Takehiko Nomura

Drug Research (Division)

Position as of April 1, 2019	Current position	Name
Senior Project Director, Chemistry	Senior Research Fellow, Innovative	Yoshiaki
Research	Drug Creation Research	Isobe
Senior Director, External Innovation	Senior Director, External Innovation	Isao Shimizu
	Development Office	isau Siliilizu

Technology Research & Development (Division)

Position as of April 1, 2019	Current position	Name
Senior Director, Process Research &	Senior Director, Process Chemistry	Mikio Sasaki
Development Laboratories	Research & Development Laboratories	WIIKIU Sasaki

Sales & Marketing (Division)

Position as of April 1, 2019	Current position	Name
Deputy Executive Director, Sales &	Senior Director, Osaka Branch	Masaichi
Marketing Division		
Senior Director, Osaka Branch		Fujimoto

Manufacturing (Division)

Position as of April 1, 2019	Current position	Name
Deputy Executive Director, Manufacturing Division Senior Director, Suzuka Plant	Senior Director, Manufacturing Management	Kenji Ueno
Senior Manufacturing Officer	Senior Director, Ibaraki Plant Senior Director, Ehime Plant Deputy Senior Director, Quality Assurance, Ibaraki Plant Deputy Senior Director, Quality Assurance, Ehime Plant	Hiroyuki Nishii
Senior Director, Manufacturing Management	Senior Director, Oita Plant	Atsushi Kaetsu
Deputy Senior Director, Manufacturing Department I, Suzuka Plant	Deputy Senior Director, Manufacturing, Suzuka Plant	Hideo Kurita
Deputy Senior Director, Manufacturing Department II, Suzuka Plant	Deputy Senior Director, Manufacturing, Ibaraki Plant	Kazuyuki Fujihara
Deputy Senior Director, Engineering, Suzuka Plant	Senior Director, Engineering	Ken Imamura
Senior Director, Oita Plant Deputy Senior Director, Manufacturing, Oita Plant	Deputy Senior Director, Manufacturing, Oita Plant	Shuzo Murata

Contact:

Public & Investor Relations Group, Corporate Governance

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)